252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
Camillo Porta(University of Pavia), Emilio Bajetta(Fondazione Lanza), Elena Verzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Chiara Paglino, Elisa Ferraris(Fondazione Salvatore Maugeri), Valentina Guadalupi(Istituti di Ricovero e Cura a Carattere Scientifico), Ilaria Imarisio(University of Pavia), Roberto Sabbatini(Azienda Ospedaliero-Universitaria di Modena), Isabella Chiappino(Azienda Ospedaliero Universitaria San Giovanni Battista), Alessandra Bearz(Centro di Riferimento Oncologico)
Cited by 23
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821